DalCor Pharmaceuticals
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2001 Boul Robert-Bourassa Suite 1700, Mo...Phone Number
(514) 508-5099Website
www.dalcorpharma.comRevenue
$5.4 MillionIndustry
About DalCor Pharmaceuticals
DalCor Pharmaceuticals is a biopharmaceutical company dedicated to addressing cardiovascular diseases through precision medicine. They are developing dalcetrapib, a pharmacogenetic treatment aimed at reducing the risk of recurrent myocardial infarction in patients with the AA genotype at the rs1967309 location in the ADCY9 gene. Currently, dalcetrapib is being evaluated in the Dal-GenE-2 Phase 3 clinical trial, following promising results from the earlier dal-GenE trial. The company targets patients with cardiovascular conditions, including those with obesity, diabetes, and hypertension.Explore more
DalCor Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to DalCor Pharmaceuticals
Compare insights from companies similar to DalCor Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
DalCor Pharmaceuticals
$5.4M
11-50
Private
$237M
-
DD
D. Michael DixonChief Financial Officer and Chef De La Direction Financière
DalCor Pharmaceuticals Tech Stack
A closer look at the technologies used by DalCor Pharmaceuticals
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding DalCor Pharmaceuticals
Sign Up For FreeTo access detailed company insights
DalCor Pharmaceuticals is a biopharmaceutical company dedicated to addressing cardiovascular diseases through precision medicine. They are developing dalcetrapib, a pharmacogenetic treatment aimed at reducing the risk of recurrent myocardial infarction in patients with the AA genotype at the rs1967309 location in the ADCY9 gene. Currently, dalcetra... Read More
